Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07154823 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Study acronym: Aquarius
StatusRecruiting
PhaseNot specified
SponsorTempus AI
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 10 → 13 locations Eligibility criteria expanded, about 16 words · Publications: details revised at 15 of 15 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 16 words
    • Publications: details revised at 15 of 15 entries
  2. Study sites: 9 to 10v9
  3. Study sites: 7 to 9v8
  4. Study sites: 6 to 7v7
  5. Study sites: 5 to 6v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 3 to 5v5
  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 3 · Start date changed from estimate of Mar 2026 to Jan 27, 2026v4 Show 2 more changesShow less
    • Study sites: 0 to 3
    • Start date changed from estimate of Mar 2026 to Jan 27, 2026
  3. Enrollment target: 50 to 550 Start date: Nov 2025 to Mar 2026 · Eligibility criteria expanded, about 173 words · Study arms: 1 to 2v3 Show 3 more changesShow less
    • Start date: Nov 2025 to Mar 2026
    • Eligibility criteria expanded, about 173 words
    • Study arms: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  4. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and/or bone marrow aspirates during their routine therapy and disease monitoring. The primary goal is to understand the association between biomarkers and real-world clinical outcomes in these patient populations.
Trial Details
NCT Number NCT07154823
Lead Sponsor Tempus AI
Conditions Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL)
Enrollment 550 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov